{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:00:10Z","timestamp":1790370010954,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02373-3","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:22:14Z","timestamp":1787275334000},"page":"1761-1768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baxdrostat: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2373_CR1","doi-asserted-by":"publisher","first-page":"1664810","DOI":"10.3389\/fphar.2025.1664810","volume":"16","author":"Y Gao","year":"2025","unstructured":"Gao Y, Mu X, Pang X. Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review. Front Pharmacol. 2025;16:1664810.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2373_CR2","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390.","journal-title":"Hypertension"},{"key":"2373_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-026-07887-2","author":"AJ Qureshi","year":"2026","unstructured":"Qureshi AJ, Tagga MRT, Khan AQ. Baxdrostat and aldosterone synthase inhibitors: a new class for treatment-resistant hypertension. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07887-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"2373_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41440-025-02468-6","volume":"49","author":"S Park","year":"2026","unstructured":"Park S. Emergence of aldosterone synthase inhibitors for treatment of difficult to treat hypertension. Hypertens Res. 2026;49(3):579\u201380.","journal-title":"Hypertens Res"},{"key":"2373_CR5","unstructured":"AstraZeneca. BAXFENDY\u2122 (baxdrostat) tablets, for oral use: US prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219878Orig1s000lbl.pdf. Accessed 21 Jul 2026."},{"key":"2373_CR6","unstructured":"AstraZeneca. Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension [media release]. 18 May 2026. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2026\/Baxdrostat-MNR-2026.html."},{"key":"2373_CR7","unstructured":"U.S. Food & Drug Administration. Drug approval package: BAXFENDY. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2026\/219878Orig1s000TOC.html. Accessed 21 Jul 2026."},{"key":"2373_CR8","unstructured":"AstraZeneca. Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension [media release]. 2 Dec 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html."},{"key":"2373_CR9","unstructured":"CinCor Pharma. CinCor Pharma in-licenses aldosterone synthase inhibitor, CIN-107, and closes $50 million Series A financing [media release]. 14 May 2019. https:\/\/5amventures.com\/wp-content\/uploads\/2019\/05\/CinCor-Pharma-In-Licenses-Aldosterone-Synthase-Inhibitor-CIN-107-and-Closes-50-Million-Series-A-Financing.pdf."},{"key":"2373_CR10","unstructured":"AstraZeneca. Acquisition of CinCor Pharma complete [media release]. 24 Feb 2023. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/astrazeneca-acquires-cincor-for-cardiorenal-asset.html#."},{"issue":"1","key":"2373_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108\u201318.","journal-title":"Hypertens Res"},{"issue":"5","key":"2373_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405.","journal-title":"N Engl J Med"},{"issue":"13, Suppl 7","key":"2373_CR13","doi-asserted-by":"publisher","first-page":"A263","DOI":"10.1016\/j.jacc.2026.02.654","volume":"87","author":"NDL Fisher","year":"2026","unstructured":"Fisher NDL, Zhou W, Olsson D, et al. Effect of baxdrostat on cortisol responsiveness in participants with uncontrolled hypertension: a phase II randomized controlled trial [abstract no 26-A-9902-ACC]. J Am Coll Cardiol. 2026;87(13, Suppl 7):A263\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"e70181","key":"2373_CR14","first-page":"1","volume":"13","author":"M Sunn\u00e5ker","year":"2025","unstructured":"Sunn\u00e5ker M, K\u00e4llgren C, Parkinson J, et al. No evidence of QTc interval prolongation with baxdrostat treatment: concentration-QTc modeling assessment. Pharmacol Res Perspect. 2025;13(e70181):1\u201311.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"2373_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"Freeman MW, Halvorsen YD, Bond M, et al. Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function. Clin Pharmacol Drug Dev. 2024;13(4):410\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"14","key":"2373_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363\u201374.","journal-title":"N Engl J Med"},{"issue":"10532","key":"2373_CR17","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","volume":"407","author":"M Azizi","year":"2026","unstructured":"Azizi M, Brown JM, Dwyer JP, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988\u201399.","journal-title":"Lancet"},{"key":"2373_CR18","unstructured":"CinCor Pharma. CinCor Pharma announces topline data for phase 2 HALO trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension [media release]. 28 Nov 2022. https:\/\/www.globenewswire.com\/news-release\/2022\/11\/28\/2563048\/0\/en\/cincor-pharma-announces-topline-data-for-phase-2-halo-trial-evaluating-selective-aldosterone-synthase-inhibitor-baxdrostat-in-uncontrolled-hypertension.html."},{"key":"2373_CR19","unstructured":"American College of Cardiology. Efficacy and safety of baxdrostat in patients with uncontrolled hypertension - HALO. 2023. https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/03\/01\/23\/34\/halo. Accessed 21 Jul 2026."},{"issue":"2","key":"2373_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","volume":"37","author":"JP Dwyer","year":"2026","unstructured":"Dwyer JP, Maklad N, Vedin O, et al. Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2026;37(2):299\u2013311.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2373_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu AF, Freeman MW, Bancos I, et al. Phase 2a study of baxdrostat in primary aldosteronism. N Engl J Med. 2025;393(5):515\u20138.","journal-title":"N Engl J Med"},{"key":"2373_CR22","unstructured":"National Institutes of Health. NCT06742723. 2022. https:\/\/clinicaltrials.gov\/study\/NCT06742723. Accessed 21 Jul 2026."},{"key":"2373_CR23","unstructured":"National Institutes of Health. NCT06268873. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06268873. Accessed 21 Jul 2026."},{"key":"2373_CR24","unstructured":"National Institutes of Health. NCT07222917. 2025. https:\/\/clinicaltrials.gov\/study\/NCT07222917. Accessed 21 Jul 2026."},{"key":"2373_CR25","unstructured":"National Institutes of Health. NCT06677060. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06677060. Accessed 21 Jul 2026."},{"key":"2373_CR26","unstructured":"National Institutes of Health. NCT07007793. 2025. https:\/\/clinicaltrials.gov\/study\/NCT07007793. Accessed 21 Jul 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02373-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:20Z","timestamp":1790366720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02373-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02373-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}